Corcept Therapeutics Incorporat (CORT) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.01
- Estimate
- $0.84
- Surprise
- +20.2%
- Revenue (period 2026-09-30)
- $340.5M
- Score at report (before → after)
- 6.1 → 6.1/10
Revenue source: xbrl.
How the report landed
Corcept Therapeutics Incorporat (CORT) beat the $0.84 estimate with adjusted EPS of $1.01 — a large 20.2% upside surprise. TrendMatrix's engine moved from Hold (6.1/10) to Sell at 6.1/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CORT Sell at 6.1/10.
2 of the last 4 quarters beat the estimate; this quarter's +20.2% surprise compares with a +101.2% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Concentration risk — Counterparty: Curant
- Concentration risk — Product: Products
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $81.93
- Price target
- $122.67
- Stop
- $77.01
- Upside to target
- +49.7%
- Reward-to-risk
- 3.6:1
The stock trades at 182.1× trailing but 19.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 18 — a level conventionally read as oversold; trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
CORT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $8.86B
- P/E (fwd)
- 19.4
- P/E (ttm)
- 182.1
- 52-week range
- $28.66–$126.38
- Off 52-week high
- 35.2%
- RSI (14)
- 18
- Volume vs avg
- 1.53×
- Score today
- 6.1/10